A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 3232 participants.
Also called NCT01848106
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,232 participants
- Sponsor
- Registry
-
NCT01848106 -
2013-001384-23
-
- Other papers using this trial's data
- Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT01848106. Randomized; no masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
- Acronym
- Regulate
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- pegnivacogin/anivamersen
- Intervention (Drug)
- Bivalirudin
- Lead sponsor
- Regado Biosciences, Inc.
- Collaborator
- The Cleveland Clinic
- Collaborator
- Duke Clinical Research Institute
- Collaborator
- Canadian VIGOUR Centre
- Collaborator
- Icahn School of Medicine at Mount Sinai
- Collaborator
- Parexel
Record details
- Record id
cardio:ct-nct01848106- Content hash
3c7a39eca60e785339196a0dc630b9f0ca2fb98a08127869973a4011166a9197